Anti-CD56 CAR T
Phase 2Cell therapy
Anti-CD56 CAR T is one of 44 biologic programs targeting Leukemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Leukemia
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Idamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Neoral
NovartisPhase 3
Novantrone
PfizerPhase 3
Leukine
SanofiPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Busulfex
Akero TherapeuticsPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-CD56 CAR T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details